8IN Stock Overview Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Syneos Health, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Syneos Health Historical stock prices Current Share Price US$40.00 52 Week High US$51.08 52 Week Low US$25.67 Beta 1.58 1 Month Change 3.63% 3 Month Change 3.63% 1 Year Change -17.96% 3 Year Change -14.53% 5 Year Change -7.26% Change since IPO 37.91%
Recent News & Updates Syneos Health, Inc. Announces Board Appointments
Syneos Health Files Form 15 Oct 11
Syneos Health, Inc. Announces Chief Executive Officer Changes Oct 05 Syneos Health, Inc. Announces Management Changes Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.
Syneos Health Names Terttu Haring President, Clinical Sites & Patients Sep 27 See more updates Syneos Health, Inc. Announces Board Appointments
Syneos Health Files Form 15 Oct 11
Syneos Health, Inc. Announces Chief Executive Officer Changes Oct 05 Syneos Health, Inc. Announces Management Changes Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.
Syneos Health Names Terttu Haring President, Clinical Sites & Patients Sep 27
Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline Sep 16
The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc Aug 29
Second quarter 2023 earnings released: EPS: US$0.008 (vs US$0.76 in 2Q 2022) Aug 10
Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc Jul 28
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer Jul 11
Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity May 26
First quarter 2023 earnings released: US$0.70 loss per share (vs US$0.45 profit in 1Q 2022) May 11 Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.
Investor sentiment improves as stock rises 15% Apr 12
Full year 2022 earnings released: EPS: US$2.59 (vs US$2.26 in FY 2021) Feb 18
Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Feb 17
Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 09 Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022
High number of new directors Nov 17
Investor sentiment deteriorated over the past week Nov 11
Third quarter 2022 earnings released: EPS: US$0.85 (vs US$0.76 in 3Q 2021) Nov 05
Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022 Nov 05
Syneos Health Adds Hub Patient Suite to Deployment Solutions Business Oct 28
Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Oct 22
Syneos Health, Inc. Announces Executive Changes Oct 15
Investor sentiment deteriorated over the past week Sep 20
Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC. Aug 19
Second quarter 2022 earnings released: EPS: US$0.76 (vs US$0.40 in 2Q 2021) Aug 03 Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022
Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 19
High number of new directors May 05 Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022
First quarter 2022 earnings released: EPS: US$0.45 (vs US$0.37 in 1Q 2021) May 01
Syneos Health Announces Executive Promotions Apr 20 Syneos Health, Inc., Annual General Meeting, May 25, 2022 Apr 13
Syneos Health, Inc. to Report Q1, 2022 Results on Apr 29, 2022 Apr 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 18 Syneos Health, Inc. Provides Earnings Guidance for the First Quarter of 2022
Syneos Health, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 02
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 25
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Independent Director Thomas Allen has left the company Nov 24
Third quarter 2021 earnings released: EPS US$0.76 (vs US$0.61 in 3Q 2020) Nov 04
Syneos Health, Inc. (NasdaqGS:SYNH) acquired StudyKIK, LLC. Sep 15
Second quarter 2021 earnings released: EPS US$0.40 (vs US$0.038 in 2Q 2020) Aug 10
Syneos Health, Inc. Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration with Site Sponsors Jun 22 Shareholder Returns 8IN DE Life Sciences DE Market 7D 1.5% -2.8% -2.6% 1Y -18.0% -5.9% 6.9%
See full shareholder returns
Return vs Market: 8IN underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is 8IN's price volatile compared to industry and market? 8IN volatility 8IN Average Weekly Movement 1.8% Life Sciences Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8IN has not had significant price volatility in the past 3 months.
Volatility Over Time: 8IN's weekly volatility has decreased from 8% to 2% over the past year.
About the Company Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
Show more Syneos Health, Inc. Fundamentals Summary How do Syneos Health's earnings and revenue compare to its market cap? 8IN fundamental statistics Market cap €4.22b Earnings (TTM ) €67.43m Revenue (TTM ) €5.13b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8IN income statement (TTM ) Revenue US$5.42b Cost of Revenue US$4.22b Gross Profit US$1.20b Other Expenses US$1.13b Earnings US$71.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/28 09:25 End of Day Share Price 2023/09/27 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Syneos Health, Inc. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Bolan Avondale Partners Eric Coldwell Baird Stewart Glickman CFRA Equity Research
Show 20 more analysts 
